Reishi Mushroom
Two Cochrane reviews looked hard at reishi and found little: no demonstrated survival benefit in cancer and no benefit at all for cardiovascular risk factors. Extremely popular, and the human data are poor.
What the science says
- Adjunct in cancer treatment Limited evidence
A Cochrane review found 5 eligible RCTs. Patients given Ganoderma lucidum alongside chemotherapy or radiotherapy were more likely to show a tumour response (RR 1.50, 95% CI 0.90-2.51), but the confidence interval crosses no effect, no trial recorded long-term survival, and the reviewers described the methodological quality as generally unsatisfying. Cochrane did not recommend it as first-line treatment.
- Cardiovascular risk factors and glycemia Limited evidence
A separate Cochrane review of 5 trials in 398 participants — with the analysable trials giving 1.4-3 g/day for 12-16 weeks to people with type 2 diabetes — found no significant effect on HbA1c (WMD -0.10%), total cholesterol, LDL, BMI, blood pressure, or triglycerides. The authors' conclusion was explicit: the evidence does not support its use for cardiovascular risk factors.
- Sleep, stress, and adaptogenic effects Limited evidence
Reishi is widely marketed for calm and sleep on the strength of rodent studies showing sedative and sleep-latency effects. There is no adequate human randomized trial for sleep or stress outcomes.
Dosage & safety
Scientific references
Where to buy
Swanson Vitamins, Reishi Mushroom Extract, Standardized, 500 mg, 90 Capsules
View on iHerbReferral link — this site may earn a commission on purchases.
Related in Immunity
- Vitamin C Limited evidence
- Zinc Moderate evidence
- Elderberry Limited evidence
- L-Lysine Limited evidence
- Echinacea Limited evidence
- Andrographis Moderate evidence